OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet, Riccardo Lencioni
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 288-306
Open Access | Times Cited: 470
Josep M. Llovet, Riccardo Lencioni
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 288-306
Open Access | Times Cited: 470
Showing 1-25 of 470 citing articles:
Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 4472
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 4472
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Amit G. Singal, Josep M. Llovet, Mark Yarchoan, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1922-1965
Open Access | Times Cited: 713
Amit G. Singal, Josep M. Llovet, Mark Yarchoan, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1922-1965
Open Access | Times Cited: 713
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet, Thierry de Baère, Laura Kulik, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 293-313
Closed Access | Times Cited: 694
Josep M. Llovet, Thierry de Baère, Laura Kulik, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 293-313
Closed Access | Times Cited: 694
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet, Augusto Villanueva, Jorge A. Marrero, et al.
Hepatology (2020) Vol. 73, Iss. S1, pp. 158-191
Open Access | Times Cited: 322
Josep M. Llovet, Augusto Villanueva, Jorge A. Marrero, et al.
Hepatology (2020) Vol. 73, Iss. S1, pp. 158-191
Open Access | Times Cited: 322
EGFR activation limits the response of liver cancer to lenvatinib
Haojie Jin, Yao Shi, Yuanyuan Lv, et al.
Nature (2021) Vol. 595, Iss. 7869, pp. 730-734
Closed Access | Times Cited: 304
Haojie Jin, Yao Shi, Yuanyuan Lv, et al.
Nature (2021) Vol. 595, Iss. 7869, pp. 730-734
Closed Access | Times Cited: 304
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, et al.
Nature Cancer (2022) Vol. 3, Iss. 4, pp. 386-401
Open Access | Times Cited: 286
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, et al.
Nature Cancer (2022) Vol. 3, Iss. 4, pp. 386-401
Open Access | Times Cited: 286
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 193
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 193
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment
Bo Hu, Mincheng Yu, Xiaolu Ma, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1718-1741
Open Access | Times Cited: 129
Bo Hu, Mincheng Yu, Xiaolu Ma, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1718-1741
Open Access | Times Cited: 129
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial
Elisabeth Dhondt, Bieke Lambert, Laurens Hermie, et al.
Radiology (2022) Vol. 303, Iss. 3, pp. 699-710
Open Access | Times Cited: 115
Elisabeth Dhondt, Bieke Lambert, Laurens Hermie, et al.
Radiology (2022) Vol. 303, Iss. 3, pp. 699-710
Open Access | Times Cited: 115
CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma
Zhichao Feng, Huiling Li, Qianyun Liu, et al.
Radiology (2022) Vol. 307, Iss. 1
Closed Access | Times Cited: 92
Zhichao Feng, Huiling Li, Qianyun Liu, et al.
Radiology (2022) Vol. 307, Iss. 1
Closed Access | Times Cited: 92
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Philipp K. Haber, Florian Castet, Miguel Torres‐Martín, et al.
Gastroenterology (2022) Vol. 164, Iss. 1, pp. 72-88.e18
Open Access | Times Cited: 90
Philipp K. Haber, Florian Castet, Miguel Torres‐Martín, et al.
Gastroenterology (2022) Vol. 164, Iss. 1, pp. 72-88.e18
Open Access | Times Cited: 90
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 90
Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 90
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study
Edward Kim, Alex Sher, Ghadi Abboud, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 9, pp. 843-850
Closed Access | Times Cited: 85
Edward Kim, Alex Sher, Ghadi Abboud, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 9, pp. 843-850
Closed Access | Times Cited: 85
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 83
Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 83
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
Chi‐Leung Chiang, K.W. Chiu, Kenneth Sik Kwan Chan, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 169-178
Closed Access | Times Cited: 76
Chi‐Leung Chiang, K.W. Chiu, Kenneth Sik Kwan Chan, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 169-178
Closed Access | Times Cited: 76
PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
Yunxing Shi, Yi Niu, Yichuan Yuan, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 56
Yunxing Shi, Yi Niu, Yichuan Yuan, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 56
Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer
Hui Yang, Jinghui Cheng, Hao Zhuang, et al.
Cancer Cell (2024) Vol. 42, Iss. 4, pp. 535-551.e8
Open Access | Times Cited: 33
Hui Yang, Jinghui Cheng, Hao Zhuang, et al.
Cancer Cell (2024) Vol. 42, Iss. 4, pp. 535-551.e8
Open Access | Times Cited: 33
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 13
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 13
Oncolytic virus VG161 in refractory hepatocellular carcinoma
Yinan Shen, Xueli Bai, Qi Zhang, et al.
Nature (2025)
Closed Access | Times Cited: 2
Yinan Shen, Xueli Bai, Qi Zhang, et al.
Nature (2025)
Closed Access | Times Cited: 2
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
Jie Mei, Yuhao Tang, Wei Wei, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 95
Jie Mei, Yuhao Tang, Wei Wei, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 95
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy
Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 883-883
Open Access | Times Cited: 63
Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 883-883
Open Access | Times Cited: 63
Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma
Jiaomeng Pan, Mao Zhang, Liangqing Dong, et al.
Autophagy (2022) Vol. 19, Iss. 4, pp. 1184-1198
Open Access | Times Cited: 55
Jiaomeng Pan, Mao Zhang, Liangqing Dong, et al.
Autophagy (2022) Vol. 19, Iss. 4, pp. 1184-1198
Open Access | Times Cited: 55
Current Imaging Diagnosis of Hepatocellular Carcinoma
Evangelos Chartampilas, Vasileios Rafailidis, Vivian Georgopoulou, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3997-3997
Open Access | Times Cited: 51
Evangelos Chartampilas, Vasileios Rafailidis, Vivian Georgopoulou, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3997-3997
Open Access | Times Cited: 51
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy
Takayuki Matsumae, Takahiro Kodama, Yuta Myojin, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3367-3367
Open Access | Times Cited: 45
Takayuki Matsumae, Takahiro Kodama, Yuta Myojin, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3367-3367
Open Access | Times Cited: 45
